Pharmazac launches Cinacalcet/Pharmazac

Pharmazac launches the new product Cinacalcet/Pharmazac in 30mg, 60mg and 90mg F.C. Tablets. Cinacalcet indicated for the treatment of secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. Hypercalemia in adults patients with Parathyroid Carcinoma (PC) and Hypercalemia in adults patient with primary (HPT) for whom Parathyroid ectomy would be indicated on basis of serum calcium levels, but who are unable to undergo parathyroidectomy.